|
Mar 27
|
Neuronetics wins FDA clearance for device to treat adolescents with depression
|
|
Mar 25
|
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
|
|
Mar 8
|
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
|
|
Mar 7
|
Neuronetics Inc (STIM) Reports Record Revenues in Q4 and Full Year 2023
|
|
Mar 7
|
Neuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call Transcript
|
|
Mar 7
|
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
|
|
Mar 6
|
Neuronetics Full Year 2023 Earnings: US$1.05 loss per share (vs US$1.38 loss in FY 2022)
|
|
Mar 6
|
Q4 2023 Neuronetics Inc Earnings Call
|
|
Mar 5
|
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 5
|
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
|
|
Dec 18
|
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
|
|
Dec 4
|
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
|
|
Dec 2
|
Investors in Neuronetics (NASDAQ:STIM) from five years ago are still down 90%, even after 40% gain this past week
|
|
Aug 21
|
NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards
|
|
Apr 28
|
Neuronetics Announces Expanded TMS Access through United HealthCare
|
|
Apr 25
|
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
|